|
Blueprint Medicines Corporation (NASDAQ: BPMC) |
|
Blueprint Medicines Corporation
BPMC's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Blueprint Medicines growth rates, revenue grew
by 126.61 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 566
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.72 %
Blueprint Medicines net loss decreased from $-134 millions, to $-56 millions in III. Quarter 2024,
• More on BPMC's Growth
|
|
Blueprint Medicines realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 176.32 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 13.73.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.21.
• More on BPMC's Valuation
|
|
|
|
|
Blueprint Medicines realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 176.32 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 13.73.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.21.
Blueprint Medicines Price to Book Ratio is at 19.31 lower than Industry Avg. of 79.96. and higher than S&P 500 Avg. of 0.01
• More on BPMC's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com